DOCSLIB.ORG

DE Medicaid MAC List Effective As of 1/5/2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DE Medicaid MAC List Effective As of 1/5/2018 OptumRx - DE Medicaid MAC List Effective as of 1/5/2018 Generic Label Name & Drug Strength Effective Date MAC Price OTHER IV THERAPY (OTIP) 10/25/2017 77.61750 PENICILLIN G POTASSIUM FOR INJ 5000000 UNIT 3/15/2017 8.00000 PENICILLIN G POTASSIUM FOR INJ 20000000 UNIT 3/15/2017 49.62000 PENICILLIN G SODIUM FOR INJ 5000000 UNIT 10/25/2017 53.57958 PENICILLIN V POTASSIUM TAB 250 MG 1/3/2018 0.05510 PENICILLIN V POTASSIUM TAB 500 MG 12/29/2017 0.10800 PENICILLIN V POTASSIUM FOR SOLN 125 MG/5ML 10/26/2017 0.02000 PENICILLIN V POTASSIUM FOR SOLN 250 MG/5ML 12/22/2017 0.02000 AMOXICILLIN (TRIHYDRATE) CAP 250 MG 12/22/2017 0.03930 AMOXICILLIN (TRIHYDRATE) CAP 500 MG 11/1/2017 0.05000 AMOXICILLIN (TRIHYDRATE) TAB 500 MG 12/28/2017 0.20630 AMOXICILLIN (TRIHYDRATE) TAB 875 MG 10/31/2017 0.08000 AMOXICILLIN (TRIHYDRATE) CHEW TAB 125 MG 10/26/2017 0.12000 AMOXICILLIN (TRIHYDRATE) CHEW TAB 250 MG 10/26/2017 0.24000 AMOXICILLIN (TRIHYDRATE) FOR SUSP 125 MG/5ML 10/28/2017 0.00667 AMOXICILLIN (TRIHYDRATE) FOR SUSP 200 MG/5ML 12/20/2017 0.01240 AMOXICILLIN (TRIHYDRATE) FOR SUSP 250 MG/5ML 12/18/2017 0.00980 AMOXICILLIN (TRIHYDRATE) FOR SUSP 400 MG/5ML 12/28/2017 0.01310 AMPICILLIN CAP 250 MG 9/26/2017 0.07154 AMPICILLIN CAP 500 MG 11/6/2017 0.24000 AMPICILLIN FOR SUSP 125 MG/5ML 3/17/2017 0.02825 AMPICILLIN FOR SUSP 250 MG/5ML 9/15/2017 0.00491 AMPICILLIN SODIUM FOR INJ 250 MG 3/15/2017 1.38900 AMPICILLIN SODIUM FOR INJ 500 MG 7/16/2016 1.02520 AMPICILLIN SODIUM FOR INJ 1 GM 12/20/2017 2.00370 AMPICILLIN SODIUM FOR IV SOLN 1 GM 7/16/2016 15.76300 AMPICILLIN SODIUM FOR INJ 2 GM 7/16/2016 4.69480 AMPICILLIN SODIUM FOR IV SOLN 2 GM 3/15/2017 7.55300 AMPICILLIN SODIUM FOR INJ 10 GM 7/16/2016 43.01000 AMPICILLIN SODIUM FOR IV SOLN 10 GM 7/16/2016 36.02500 DICLOXACILLIN SODIUM CAP 250 MG 12/20/2017 0.32220 DICLOXACILLIN SODIUM CAP 500 MG 12/29/2017 0.59680 NAFCILLIN SODIUM FOR INJ 1 GM 7/16/2016 6.26120 NAFCILLIN SODIUM FOR INJ 2 GM 9/16/2016 11.48520 NAFCILLIN SODIUM FOR IV SOLN 2 GM 12/15/2015 37.13028 NAFCILLIN SODIUM FOR INJ 10 GM 7/16/2016 84.48759 OXACILLIN SODIUM FOR INJ 1 GM (BASE EQUIVALENT) 3/15/2017 8.00000 OXACILLIN SODIUM FOR INJ 2 GM (BASE EQUIVALENT) 3/15/2017 16.00000 OXACILLIN SODIUM FOR INJ 10 GM (BASE EQUIVALENT) 3/15/2017 87.30000 AMOXICILLIN & K CLAVULANATE TAB 250-125 MG 12/29/2017 3.85230 AMOXICILLIN & K CLAVULANATE TAB 500-125 MG 11/1/2017 0.15600 AMOXICILLIN & K CLAVULANATE TAB 875-125 MG 12/18/2017 0.33780 AMOXICILLIN & K CLAVULANATE CHEW TAB 200-28.5 MG 10/12/2017 0.88661 AMOXICILLIN & K CLAVULANATE CHEW TAB 400-57 MG 12/22/2017 2.11880 AMOXICILLIN & K CLAVULANATE FOR SUSP 200-28.5 MG/5ML 12/28/2017 0.04190 AMOXICILLIN & K CLAVULANATE FOR SUSP 250-62.5 MG/5ML 10/28/2017 0.39333 AMOXICILLIN & K CLAVULANATE FOR SUSP 400-57 MG/5ML 12/29/2017 0.06230 AMOXICILLIN & K CLAVULANATE FOR SUSP 600-42.9 MG/5ML 10/31/2017 0.07500 AMOXICILLIN & K CLAVULANATE TAB ER 12HR 1000-62.5 MG 10/26/2017 4.14286 AMPICILLIN & SULBACTAM SODIUM FOR INJ 1.5 (1-0.5) GM 3/15/2017 2.11220 AMPICILLIN & SULBACTAM SODIUM FOR INJ 3 (2-1) GM 7/16/2016 3.93910 AMPICILLIN & SULBACTAM SODIUM FOR INJ 15 (10-5) GM 3/15/2017 16.23000 AMPICILLIN & SULBACTAM SODIUM FOR IV SOLN 15 (10-5) GM 3/15/2017 16.15000 PIPERACILLIN SOD-TAZOBACTAM SOD FOR INJ 2.25 GM (2-0.25 GM) 9/15/2017 1.31111 PIPERACILLIN SOD-TAZOBACTAM NA FOR INJ 3.375 GM (3-0.375 GM) 5/25/2017 4.03920 PIPERACILLIN SOD-TAZOBACTAM SOD FOR INJ 4.5 GM (4-0.5 GM) 5/17/2017 5.61000 PIPERACILLIN SOD-TAZOBACTAM SOD FOR INJ 13.5 GM (12-1.5 GM) 10/25/2017 61.96500 PIPERACILLIN SOD-TAZOBACTAM SOD FOR INJ 40.5 GM (36-4.5 GM) 3/15/2017 80.25940 CEFADROXIL CAP 500 MG 12/28/2017 0.17750 CEFADROXIL TAB 1 GM 12/20/2017 1.71910 CEFADROXIL FOR SUSP 250 MG/5ML 12/20/2017 0.17000 CEFADROXIL FOR SUSP 500 MG/5ML 10/26/2017 0.26000 CEFAZOLIN SODIUM FOR INJ 500 MG 9/2/2017 1.35262 CEFAZOLIN SODIUM FOR INJ 1 GM 8/25/2017 0.80825 CEFAZOLIN SODIUM FOR IV SOLN 1 GM 10/25/2017 2.76624 CEFAZOLIN SODIUM FOR INJ 10 GM 7/16/2016 6.13690 CEFAZOLIN IN D5W INJ 1 GM/50ML 7/16/2016 0.12320 CEFAZOLIN SODIUM-DEXTROSE IV SOLUTION 2 GM/100ML-4% 3/15/2017 0.09250 CEFAZOLIN SODIUM FOR IV SOLN 1 GM AND DEXTROSE 4% 10/25/2017 4.19815 CEFAZOLIN SODIUM FOR IV SOLN 2 GM AND DEXTROSE 3% 3/15/2017 7.15417 CEPHALEXIN CAP 250 MG 12/29/2017 0.05080 CEPHALEXIN CAP 500 MG 10/31/2017 0.06800 CEPHALEXIN CAP 750 MG 10/26/2017 4.75000 CEPHALEXIN TAB 250 MG 10/26/2017 0.92000 CEPHALEXIN TAB 500 MG 10/26/2017 1.84000 CEPHALEXIN FOR SUSP 125 MG/5ML 10/26/2017 0.09000 CEPHALEXIN FOR SUSP 250 MG/5ML 11/4/2017 0.09500 CEFACLOR CAP 250 MG 10/26/2017 0.41290 CEFACLOR CAP 500 MG 10/26/2017 0.76130 CEFACLOR FOR SUSP 250 MG/5ML 7/14/2017 1.16620 CEFACLOR MONOHYDRATE TAB ER 12HR 500 MG 7/16/2016 10.80090 CEFOTETAN DISODIUM FOR INJ 1 GM 3/15/2017 19.22000 CEFOTETAN DISODIUM FOR INJ 2 GM 3/15/2017 37.60000 CEFOXITIN SODIUM FOR IV SOLN 1 GM 3/15/2017 3.95000 CEFOXITIN SODIUM FOR IV SOLN 2 GM 7/16/2016 6.60000 CEFOXITIN SODIUM FOR INJ 10 GM 3/15/2017 27.50000 CEFPROZIL TAB 250 MG 12/28/2017 0.56590 CEFPROZIL TAB 500 MG 11/27/2017 0.86000 CEFPROZIL FOR SUSP 125 MG/5ML 12/28/2017 0.11070 CEFPROZIL FOR SUSP 250 MG/5ML 12/29/2017 0.18860 CEFUROXIME AXETIL TAB 250 MG 12/19/2017 0.55000 CEFUROXIME AXETIL TAB 500 MG 11/1/2017 0.95000 CEFUROXIME SODIUM FOR INJ 750 MG 7/16/2016 2.40064 CEFUROXIME SODIUM FOR INJ 1.5 GM 7/16/2016 3.82800 CEFUROXIME SODIUM FOR IV SOLN 1.5 GM 7/14/2017 4.98127 CEFUROXIME SODIUM FOR INJ 7.5 GM 3/15/2017 19.40000 CEFDINIR CAP 300 MG 12/18/2017 0.35250 CEFDINIR FOR SUSP 125 MG/5ML 10/31/2017 0.15000 CEFDINIR FOR SUSP 250 MG/5ML 11/3/2017 0.20000 CEFIXIME FOR SUSP 100 MG/5ML 10/28/2017 2.70000 CEFIXIME FOR SUSP 200 MG/5ML 10/26/2017 5.27000 CEFPODOXIME PROXETIL TAB 100 MG 10/26/2017 3.75000 CEFPODOXIME PROXETIL TAB 200 MG 10/26/2017 4.00000 CEFPODOXIME PROXETIL FOR SUSP 50 MG/5ML 5/25/2017 0.59180 CEFPODOXIME PROXETIL FOR SUSP 100 MG/5ML 10/26/2017 0.96000 CEFOTAXIME SODIUM FOR INJ 500 MG 3/15/2017 1.45500 CEFOTAXIME SODIUM FOR INJ 1 GM 7/16/2016 1.57300 CEFOTAXIME SODIUM FOR INJ 2 GM 3/15/2017 3.28280 CEFOTAXIME SODIUM FOR INJ 10 GM 7/16/2016 19.88800 CEFTAZIDIME FOR INJ 1 GM 11/23/2017 3.80000 CEFTAZIDIME FOR IV SOLN 1 GM 3/15/2017 5.36000 CEFTAZIDIME FOR INJ 2 GM 3/15/2017 8.45000 CEFTAZIDIME FOR IV SOLN 2 GM 3/15/2017 10.89000 CEFTAZIDIME FOR INJ 6 GM 7/16/2016 18.65600 CEFTAZIDIME FOR IV SOLN 1 GM/50ML AND DEXTROSE 5% 10/25/2017 11.74020 CEFTAZIDIME FOR IV SOLN 2 GM/50ML AND DEXTROSE 5% 3/15/2017 16.08750 CEFTIBUTEN CAP 400 MG 2/17/2017 20.40510 CEFTIBUTEN FOR SUSP 180 MG/5ML 10/26/2017 6.20250 CEFTRIAXONE SODIUM FOR INJ 250 MG 10/26/2017 0.71000 CEFTRIAXONE SODIUM FOR INJ 500 MG 10/26/2017 0.90000 CEFTRIAXONE SODIUM FOR INJ 1 GM 12/29/2017 1.49560 CEFTRIAXONE SODIUM FOR IV SOLN 1 GM 5/25/2017 3.80460 CEFTRIAXONE SODIUM FOR INJ 2 GM 12/28/2017 2.00000 CEFTRIAXONE SODIUM FOR IV SOLN 2 GM 3/15/2017 6.84000 CEFTRIAXONE SODIUM FOR INJ 10 GM 7/16/2016 19.56614 CEFTRIAXONE SODIUM (BULK) FOR INJ 100 GM 10/25/2017 739.50000 CEFTRIAXONE SODIUM IN DEXTROSE INJ 20 MG/ML 7/16/2016 0.39023 CEFTRIAXONE SODIUM IN DEXTROSE INJ 40 MG/ML 3/15/2017 1.50580 CEFTRIAXONE SODIUM FOR IV SOLN 1 GM AND DEXTROSE 3.74% 10/25/2017 13.48865 CEFTRIAXONE SODIUM FOR IV SOLN 2 GM AND DEXTROSE 2.22% 3/15/2017 20.76667 CEFEPIME HCL IV SOLN 1 GM/50ML 10/25/2017 0.67728 CEFEPIME HCL IV SOLN 2 GM/100ML 10/25/2017 0.54290 CEFEPIME HCL FOR INJ 1 GM 9/15/2017 1.16096 CEFEPIME HCL FOR INJ 2 GM 2/17/2017 6.47190 CEFEPIME HCL AND DEXTROSE 5% FOR IV SOLN 1 GM/50ML 10/25/2017 13.17458 CEFEPIME HCL AND DEXTROSE 5% FOR IV SOLN 2 GM/50ML 10/25/2017 19.52365 ERYTHROMYCIN TAB 250 MG 12/29/2017 11.37220 ERYTHROMYCIN TAB 500 MG 5/25/2017 15.91088 ERYTHROMYCIN W/ DELAYED RELEASE PARTICLES CAP 250 MG 12/29/2017 4.23210 ERYTHROMYCIN ETHYLSUCCINATE TAB 400 MG 11/23/2017 11.93000 ERYTHROMYCIN ETHYLSUCCINATE FOR SUSP 200 MG/5ML 10/31/2017 2.15000 AZITHROMYCIN TAB 250 MG 11/24/2017 0.33333 AZITHROMYCIN TAB 500 MG 12/28/2017 0.72410 AZITHROMYCIN TAB 600 MG 12/29/2017 1.68620 AZITHROMYCIN FOR SUSP 100 MG/5ML 11/3/2017 0.53000 AZITHROMYCIN FOR SUSP 200 MG/5ML 11/11/2017 0.26733 AZITHROMYCIN IV FOR SOLN 500 MG 2/17/2017 3.29664 AZITHROMYCIN POWD PACK FOR SUSP 1 GM 10/28/2017 18.66667 CLARITHROMYCIN TAB 250 MG 12/29/2017 0.43270 CLARITHROMYCIN TAB 500 MG 12/18/2017 0.48980 CLARITHROMYCIN FOR SUSP 125 MG/5ML 10/26/2017 0.38000 CLARITHROMYCIN FOR SUSP 250 MG/5ML 11/16/2017 0.86000 CLARITHROMYCIN TAB ER 24HR 500 MG 10/26/2017 2.78333 DEMECLOCYCLINE HCL TAB 150 MG 10/26/2017 1.63110 DEMECLOCYCLINE HCL TAB 300 MG 10/26/2017 3.04396 DOXYCYCLINE MONOHYDRATE CAP 50 MG 12/21/2017 0.13880 DOXYCYCLINE MONOHYDRATE CAP 75 MG 10/28/2017 9.13000 DOXYCYCLINE MONOHYDRATE CAP 100 MG 11/4/2017 0.22000 DOXYCYCLINE MONOHYDRATE CAP 150 MG 11/23/2017 1.18950 DOXYCYCLINE MONOHYDRATE TAB 50 MG 12/29/2017 0.37240 DOXYCYCLINE MONOHYDRATE TAB 75 MG 10/26/2017 0.47760 DOXYCYCLINE MONOHYDRATE TAB 100 MG 12/28/2017 0.37400 DOXYCYCLINE MONOHYDRATE TAB 150 MG 12/29/2017 4.71890 DOXYCYCLINE MONOHYDRATE FOR SUSP 25 MG/5ML 10/26/2017 0.23333 DOXYCYCLINE HYCLATE CAP 50 MG 10/26/2017 0.42000 DOXYCYCLINE HYCLATE CAP 100 MG 12/19/2017 0.26040 DOXYCYCLINE HYCLATE TAB 20 MG 12/17/2017 0.31000 DOXYCYCLINE HYCLATE TAB 75 MG 11/21/2017 10.06667 DOXYCYCLINE HYCLATE TAB 100 MG 10/31/2017 0.32000 DOXYCYCLINE HYCLATE TAB 150 MG 12/12/2017 13.98333 DOXYCYCLINE HYCLATE TAB DELAYED RELEASE 50 MG 10/26/2017 8.35833 DOXYCYCLINE HYCLATE TAB DELAYED RELEASE 75 MG 11/23/2017 5.83000 DOXYCYCLINE HYCLATE TAB DELAYED RELEASE 100 MG 10/26/2017 5.50000 DOXYCYCLINE HYCLATE TAB DELAYED
Load more

Recommended publications
  • Magnesium Causes Nitric Oxide Independent Coronary Artery Vasodilation in Humans Heart: First Published As 10.1136/Hrt.86.2.212 on 1 August 2001
    212 Heart 2001;86:212–216 Magnesium causes nitric oxide independent coronary artery vasodilation in humans Heart: first published as 10.1136/hrt.86.2.212 on 1 August 2001. Downloaded from H Teragawa, M Kato, T Yamagata, H Matsuura, G Kajiyama Abstract Objective—To determine how magnesium aVects human coronary arteries and whether endothe- lium derived nitric oxide (EDNO) is involved in the coronary arterial response to magnesium. Design—Quantitative coronary angiography and Doppler flow velocity measurements were used to determine the eVects of the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA) on magnesium induced dilation of the epicardial and resistance coronary arteries. Setting—Hiroshima University Hospital a tertiary cardiology centre. Patients—17 patients with angiographically normal coronary arteries. Interventions—Magnesium sulfate (MgSO4) (0.02 mmol/min and 0.2 mmol/min) was infused for two minutes into the left coronary ostium before and after intracoronary infusion of L-NMMA. Main outcome measures—Diameter of the proximal and distal segments of the epicardial cor- onary arteries and coronary blood flow. Results—At a dose of 0.02 mmol/min, MgSO4 did not aVect the coronary arteries. At a dose of 0.2 mmol/min, MgSO4 caused coronary artery dilation (mean (SEM) proximal diameter 3.00 (0.09) to 3.11 (0.09) mm; distal 1.64 (0.06) to 1.77 (0.07) mm) and increased coronary blood flow (79.3 (7.5) to 101.4 (9.9) ml/min, p < 0.001 v baseline for all). MgSO4 increased the changes in these parameters after the infusion of L-NMMA (p < 0.001 v baseline).
    [Show full text]
  • THE ACCUMULATION and DISTRIBUTION of EVANS BLUE in the KIDNEY of RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seign
    THE ACCUMULATION AND DISTRIBUTION OF EVANS BLUE IN THE KIDNEY OF RATS FED NORMAL OR LOW MAGNESIUM DIETS by George Williams Seignious, IV Thesis submitted to the Graduate Faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE in ! Biochemistry and Nutrition APPROVED: G. E. Bunce, Chairman R. E. Webb ______ fl" ________ M;O. ......... ..;:;...; ___'"";:,....:; __.;..,. ___ _ _.. ''-.::;,,/ ___ , _______ ,_.._~_ M. H. Samli R. G. Saacke August, 1973 Blacksburg, Virginia . l\CKNOWLEDGMEN',rS The author of this thesis would like to e~press his deepest thanks and gra'titU;de to for his.continued help, advice, and . ·. .. : .. - understanding which made this thesis possible •. A special note of ·"· thanks is expressed.to whos_e invaluable help, advice arid suggestions aided greatly the author's efforts. The author would also like to thank for his. help and advice in the lab and all the other graduate students who made the author's stay at Virginia.Tech i{ very pleasant _one. Thanks is expressed to the author's wife, , for .her love, understanding, encouragement, and typing which· enabled the completion of this thesis. Also the author would like.to thank his parents for their lc;rving support and financial assistance. ii 'TABLE OF CONTENTS ACKNOWLEDGMENTS ii. TABLE OF CONTENTS . iii I,.IST OF TABLES iv LIST OF FIGURES Vi LIST OF SELECTED CHEMICAL STRUCTURES vii LIST OF·ABBREVIATIONS viii INTRODUCTION 1 LITERATURE REVIEW 5 EXPERIMENTAL PROCEDURES RESULTS 33 DISCUSSION 74 SUMMARY 82 REFERENCES 85 VITA 88 iii ~· ,,;.
    [Show full text]
  • VOLUME 7 2 . No. 4 . AUGUST 2 0
    VOLUME 72 . No.4 . AUGUST 2020 © 2020 EDIZIONI MINERVA MEDICA Minerva Pediatrica 2020 August;72(4):288-311 Online version at http://www.minervamedica.it DOI: 10.23736/S0026-4946.20.05861-2 REVIEW MANAGEMENT OF THE MAIN ENDOCRINE AND DIABETIC DISORDERS IN CHILDREN Current treatment for polycystic ovary syndrome: focus on adolescence Maria E. STREET 1 *, Francesca CIRILLO 1, Cecilia CATELLANI 1, 2, Marco DAURIZ 3, 4, Pietro LAZZERONI 1, Chiara SARTORI 1, Paolo MOGHETTI 4 1Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Reggio Emilia, Italy; 2Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy; 3Section of Endocrinology and Diabetes, Department of Internal Medicine, Bolzano General Hospital, Bolzano, Italy; 4Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Hospital Trust of Verona, Verona, Italy *Corresponding author: Maria E. Street, Division of Pediatric Endocrinology and Diabetology, Department of Mother and Child, Azienda USL – IRCCS di Reggio Emilia, Viale Risorgimento 80, 42123 Reggio Emilia, Italy. E-mail: [email protected] ABSTRACT Polycystic ovary syndrome (PCOS) is the most frequent endocrine disorder in women and it is associated with an in- creased rate of infertility. Its etiology remains largely unknown, although both genetic and environmental factors play a role. PCOS is characterized by insulin resistance, metabolic disorders and low-grade chronic inflammation. To date, the treatment of PCOS is mainly symptomatic and aimed at reducing clinical signs of hyperandrogenism (hirsutism and acne), at improving menstrual cyclicity and at favoring ovulation. Since PCOS pathophysiology is still largely unknown, the therapeutic interventions currently in place are rarely cause-specific.
    [Show full text]
  • Formaldehyde? Formaldehyde Is a Colorless, Strong-Smelling Gas Used to Make Household Products and Building Materials, Furniture, and Paper Products
    What is formaldehyde? Formaldehyde is a colorless, strong-smelling gas used to make household products and building materials, furniture, and paper products. It is used in particleboard, plywood, and fiberboard. What products contain formaldehyde? Formaldehyde can be found in most homes and buildings. Formaldehyde is also released into the air from many products you may use in your home. Because formaldehyde breaks down in air, you may breathe it in from such products as • carpet cleaner • gas cookers and open fireplaces, • cosmetics, • glue, • fabric softeners, • household cleaners, and • fingernail polish and hardeners, • latex paint. Burning cigarettes and other tobacco products also release formaldehyde. Products give off different amounts of formaldehyde. For example, • fingernail polish gives off more formaldehyde than do plywood and new carpet, and • some paper products—such as grocery bags and paper towels—give off only small amounts of formaldehyde. Our bodies even produce some formaldehyde, although only in small amounts. Will I get sick if I breathe or touch formaldehyde? You might not get sick if you breathe or touch formaldehyde, but if you have breathed or touched formaldehyde you may have symptoms such as • sore, itchy, or burning eyes, nose, or throat; • skin rash; or • breathing symptoms such as chest tightness, coughing, and shortness of breath. People who are more likely to get sick from being around formaldehyde are children, the elderly, and people with asthma. Formaldehyde may affect children more than it does adults. If you think your child may have been around formaldehyde, and he or she has symptoms contact a doctor. You should also know that: babies are not likely to get formaldehyde from breast milk, and you may be more sensitive to formaldehyde if you have asthma.
    [Show full text]
  • Method 323—Measurement of Formaldehyde Emissions from Natural Gas-Fired Stationary Sources—Acetyl Acetone Derivitization Method
    While we have taken steps to ensure the accuracy of this Internet version of the document, it is not the official version. Please refer to the official version in the FR publication, which appears on the Government Printing Office's FDSys website (http://www.gpo.gov/fdsys/browse/collectionCfr.action?). Method 323—Measurement of Formaldehyde Emissions From Natural Gas-Fired Stationary Sources—Acetyl Acetone Derivitization Method 1.0 Introduction. This method describes the sampling and analysis procedures of the acetyl acetone colorimetric method for measuring formaldehyde emissions in the exhaust of natural gas-fired, stationary combustion sources. This method, which was prepared by the Gas Research Institute (GRI), is based on the Chilled Impinger Train Method for Methanol, Acetone, Acetaldehyde, Methyl Ethyl Ketone, and Formaldehyde (Technical Bulletin No. 684) developed and published by the National Council of the Paper Industry for Air and Stream Improvement, Inc. (NCASI). However, this method has been prepared specifically for formaldehyde and does not include specifications (e.g., equipment and supplies) and procedures (e.g., sampling and analytical) for methanol, acetone, acetaldehyde, and methyl ethyl ketone. To obtain reliable results, persons using this method should have a thorough knowledge of at least Methods 1 and 2 of 40 CFR part 60, appendix A–1; Method 3 of 40 CFR part 60, appendix A–2; and Method 4 of 40 CFR part 60, appendix A–3. 1.1 Scope and Application 1.1.1 Analytes. The only analyte measured by this method is formaldehyde (CAS Number 50–00–0). 1.1.2 Applicability. This method is for analyzing formaldehyde emissions from uncontrolled and controlled natural gas-fired, stationary combustion sources.
    [Show full text]
  • Study Protocol and Statistical Analysis Plan
    Confidential Clinical study protocol number: J1228 Page 1 Version Date: May 7, 2018 IRB study Number: NA_00067315 A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma Principal Investigator: Douglas E. Gladstone, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1650 Orleans Street, CRBI-287 Baltimore, MD 21287 Phone: 410-955-8781 Fax: 410-614-1005 Email: [email protected] IRB Protocol Number: NA_00067315 Study Number: J1228 IND Number: EXEMPT Novartis Protocol Number: CRAD001NUS157T Version: May 7, 2018 Co-Investigators: Jonathan Powell 1650 Orleans Street, CRBI-443 Phone: 410-502-7887 Fax: 443-287-4653 Email: [email protected] Richard Jones 1650 Orleans Street, CRBI-244 Phone: 410-955-2006 Fax: 410-614-7279 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 2 Version Date: May 7, 2018 IRB study Number: NA_00067315 Satish Shanbhag Johns Hopkins Bayview Medical Center 301 Building, Suite 4500 4940 Eastern Ave Phone: 410-550-4061 Fax: 410-550-5445 Email: [email protected] Statisticians: Gary Rosner Phone: 410-955-4884 Email: [email protected] Marianna Zahurak Phone: 410-955-4219 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 3 Version Date: May 7, 2018 IRB study Number: NA_00067315 Table of contents Table of contents ......................................................................................................................... 3 List of abbreviations
    [Show full text]
  • Toxicological Profile for Formaldehyde
    TOXICOLOGICAL PROFILE FOR FORMALDEHYDE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Agency for Toxic Substances and Disease Registry July 1999 FORMALDEHYDE ii DISCLAIMER The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry. FORMALDEHYDE iii UPDATE STATEMENT Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at: Agency for Toxic Substances and Disease Registry Division of Toxicology/Toxicology Information Branch 1600 Clifton Road NE, E-29 Atlanta, Georgia 30333 FORMALDEHYDE vii QUICK REFERENCE FOR HEALTH CARE PROVIDERS Toxicological Profiles are a unique compilation of toxicological information on a given hazardous substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation of available toxicologic and epidemiologic information on a substance. Health care providers treating patients potentially exposed to hazardous substances will find the following information helpful for fast answers to often-asked questions. Primary Chapters/Sections of Interest Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating patients about possible exposure to a hazardous substance. It explains a substance’s relevant toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of the general health effects observed following exposure. Chapter 2: Health Effects: Specific health effects of a given hazardous compound are reported by route of exposure, by type of health effect (death, systemic, immunologic, reproductive), and by length of exposure (acute, intermediate, and chronic).
    [Show full text]
  • The Decomposition Kinetics of Peracetic Acid and Hydrogen Peroxide in Municipal Wastewaters
    Disinfection Forum No 10, October 2015 The Decomposition Kinetics of Peracetic Acid and Hydrogen Peroxide in Municipal Wastewaters INTRODUCTION Efficient control of microbial populations in municipal wastewater using peracetic acid (PAA) requires an understanding of the PAA decomposition kinetics. This knowledge is critical to ensure the proper dosing of PAA needed to achieve an adequate concentration within the contact time of the disinfection chamber. In addition, the impact of PAA on the environment, post-discharge into the receiving water body, also is dependent upon the longevity of the PAA in the environment, before decomposing to acetic acid, oxygen and water. As a result, the decomposition kinetics of PAA may have a significant impact on aquatic and environmental toxicity. PAA is not manufactured as a pure compound. The solution exists as an equilibrium mixture of PAA, hydrogen peroxide, acetic acid, and water: ↔ + + Acetic Acid Hydrogen Peroxide Peracetic Acid Water PeroxyChem’s VigorOx® WWT II Wastewater Disinfection Technology contains 15% peracetic acid by weight and 23% hydrogen peroxide as delivered. Although hydrogen peroxide is present in the formulation, peracetic acid is considered to be the active component for disinfection1 in wastewater. There have been several published studies investigating the decomposition kinetics of PAA in different water matrices, including municipal wastewater2-7. Yuan7 states that PAA may be consumed in the following three competitive reactions: 1. Spontaneous decomposition 2 CH3CO3H à 2 CH3CO2H + O2 Eq (1) 2. Hydrolysis CH3CO3H + H2O à CH3CO2H + H2O2 Eq (2) 3. Transition metal catalyzed decomposition + CH3CO3H + M à CH3CO2H + O2 + other products Eq (3) At neutral pH’s, both peracetic acid and hydrogen peroxide can be rapidly consumed by these reactions7 (hydrogen peroxide will decompose to water and oxygen via 2H2O2 à 2H2O + O2).
    [Show full text]
  • Opposing Effects of Dehydroepiandrosterone And
    European Journal of Endocrinology (2000) 143 687±695 ISSN 0804-4643 EXPERIMENTAL STUDY Opposing effects of dehydroepiandrosterone and dexamethasone on the generation of monocyte-derived dendritic cells M O Canning, K Grotenhuis, H J de Wit and H A Drexhage Department of Immunology, Erasmus University Rotterdam, The Netherlands (Correspondence should be addressed to H A Drexhage, Lab Ee 838, Department of Immunology, Erasmus University, PO Box 1738, 3000 DR Rotterdam, The Netherlands; Email: [email protected]) Abstract Background: Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulating steroid hormone, of which the effects on the development of dendritic cells (DC) are unknown. The effects of DHEA often oppose those of the other adrenal glucocorticoid, cortisol. Glucocorticoids (GC) are known to suppress the immune response at different levels and have recently been shown to modulate the development of DC, thereby influencing the initiation of the immune response. Variations in the duration of exposure to, and doses of, GC (particularly dexamethasone (DEX)) however, have resulted in conflicting effects on DC development. Aim: In this study, we describe the effects of a continuous high level of exposure to the adrenal steroid DHEA (1026 M) on the generation of immature DC from monocytes, as well as the effects of the opposing steroid DEX on this development. Results: The continuous presence of DHEA (1026 M) in GM-CSF/IL-4-induced monocyte-derived DC cultures resulted in immature DC with a morphology and functional capabilities similar to those of typical immature DC (T cell stimulation, IL-12/IL-10 production), but with a slightly altered phenotype of increased CD80 and decreased CD43 expression (markers of maturity).
    [Show full text]
  • Triclosan Disrupts Thyroid Hormones: Mode-Of-Action, Developmental Susceptibility, and Determination of Human Relevance
    Triclosan Disrupts Thyroid Hormones: Mode-of-Action, Developmental Susceptibility, and Determination of Human Relevance Katie Beth Paul “A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Curriculum of Toxicology.” Chapel Hill 2011 Approved by: Kim L. R. Brouwer, Pharm.D., Ph.D. Kevin M. Crofton, Ph.D. Michael J. DeVito, Ph.D. Philip C. Smith, Ph.D James A. Swenberg, D.V.M., Ph.D. ©2011 Katie Beth Paul ALL RIGHTS RESERVED ii Abstract Katie Beth Paul Triclosan Disrupts Thyroid Hormones: Mode-of-Action, Developmental Susceptibility, and Determination of Human Relevance (Under the direction of Kevin M. Crofton, Ph.D.) Preliminary study demonstrated that triclosan (TCS), a bacteriostat in myriad consumer products, decreases serum thyroxine (T4) in rats. Adverse neurodevelopmental consequences result from thyroid hormone (TH) disruption; therefore determination of whether TCS disrupts THs during development, its mode-of-action (MOA), and the human relevance is critical. This research tested the hypothesis that TCS disrupts THs via activation of pregnane X and constitutive androstane receptors (PXR, CAR), mediating Phase I-II enzyme and hepatic transporter expression and protein changes, thereby increasing catabolism and elimination of THs, resulting in decreased TH concentrations. For Aim One, the hypothesized MOA was assessed using weanling female Long-Evans rats orally exposed to TCS (0-1000 mg/kg/day) for four days. Serum T4 decreased 35% at 300 mg/kg/day. Activity and expression of markers of Phase I (Cyp2b, Cyp3a1) and Phase II (Ugt1a1, Sult1c1) metabolism were moderately induced, consistent with PXR and/or CAR activation and increased hepatic catabolism.
    [Show full text]
  • University of Groningen Discovery of a Eugenol Oxidase From
    University of Groningen Discovery of a eugenol oxidase from Rhodococcus sp strain RHA1 Jin, J.F.; Mazon, H.; van den Heuvel, R.H.H.; Janssen, D.B.; Fraaije, M.W. Published in: Febs Journal DOI: 10.1111/j.1742-4658.2007.05767.x IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2007 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Jin, J. F., Mazon, H., van den Heuvel, R. H. H., Janssen, D. B., & Fraaije, M. W. (2007). Discovery of a eugenol oxidase from Rhodococcus sp strain RHA1. Febs Journal, 274(9), 2311 - 2321. https://doi.org/10.1111/j.1742-4658.2007.05767.x Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 23-09-2021 Discovery of a eugenol oxidase from Rhodococcus sp.
    [Show full text]
  • An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia Without Diabetes Joseph C
    Case Reports An Open-Label Pilot Trial of Alpha-Lipoic Acid for Weight Loss in Patients with Schizophrenia without Diabetes Joseph C. Ratliff1 , Laura B. Palmese 1, Erin L. Reutenauer 1, Cenk Tek 1 Abstract A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this ef- fect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg). Clinical Trial Registra- tion: NCT01355952. Key Words: Schizophrenia, Obesity, Schizoaffective Disorder, Alpha-Lipoic Acid Introduction dependent protein kinase (AMPK) in the hypothalamus Antipsychotic medications appear to induce weight (4). In the periphery, AMPK increases energy utilization; gain, which results in increased rates of obesity in schizo- AMPK activity in the hypothalamus increases appetite. phrenia (1). Schizophrenia patients have significantly short- Several highly orexigenic (stimulates appetite) antipsy- er life expectancy than the general population (2); most of chotics such as clozapine, olanzapine, and quetiapine are this excess mortality is attributed to diabetes and cardiovas- shown to activate AMPK in the hypothalamus in animal cular disease (3); weight gain is a significant contributor to studies whereas other antipsychotic medications do not (4).
    [Show full text]